P embrolizumab, a programmed cell death receptor 1 (PD-1) inhibitor, has been used effectively for treatment of metastatic melanoma. 1 Reported cutaneous adverse events ascribed to PD-1 inhibitors include lichenoid reactions such as lichen planus of the skin and oral mucosa, lichen planus pemphigoides, and lichenoid drug eruptions, as well as alopecia areata and vitiligo. [2] [3] [4] [5] We present a patient with metastatic melanoma who had lichen planopilaris (LPP) after receiving pembrolizumab. We find no previous report in the literature of LPP in association with PD-1 inhibitors.
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CASE REPORT
A 47-year-old man presented with a bleeding nodular growth on the scalp, diagnosed from biopsy results as melanoma. A wide local excision showed no evidence of residual disease, and sentinel lymph node biopsy result was negative for metastases. Several months later, the patient had a new scalp nodule, with pathology findings consistent with those of metastatic melanoma. Positron emission tomographyecomputed tomography (PET-CT) found 2 fluorodeoxyglucose (FDG)-avid lesions in the left posterior scalp and right suboccipital region concerning for multifocal bilateral metastases. After 3 cycles of pembrolizumab, the patient noted growth and erythema of the nodule and palpable lymphadenopathy. A repeat PET-CT confirmed that the nodule in left posterior scalp had increased in size and FDG uptake, and there were new mildly FDGavid cervical lymph nodes. He then received 2 cycles of ipilimumab leading to a clinical remission.
Approximately 2 months after his first pembrolizumab infusion and before starting ipilimumab, oral ulcers developed consistent with oral lichen planus. Several weeks after receiving ipilimumab, he noted gingival swelling and tenderness, hair loss, and scalp pruritus. Physical exam found round incomplete patches of alopecia with perifollicular erythema and scaling on the parietal scalp (Fig 1) , diffuse alopecia on the vertex scalp, depigmentation of the hair overlying the metastatic melanoma nodule, and shallow ulcers on the lateral aspects of the tongue. Cutaneous lichenoid papules and oral Wickham striae were not observed. Scalp biopsy found prominent lichenoid inflammation limited to the upper portion of the outer root sheath of the majority of hair follicles, perifollicular fibrosis, and focal follicular scarring (Fig 2, A-D) . Based on these findings and clinical presentation, a diagnosis of LPP was made.
Several weeks after completing treatment with ipilimumab and 2 to 3 months after the course of pembrolizumab, the patient received treatment with prednisone, which improved his oral ulcers and resulted in hair regrowth. Additionally, he was given 1 month of systemic minocycline and topical 
DISCUSSION
Given that lichenoid reactions (including lichen planus and lichen planus pemphigoides), alopecia areata, and vitiligo have all been reported previously in association with PD-1 inhibitors, it is not surprising that LPP could also be associated. Checkpoint inhibitors such as pembrolizumab and nivolumab have shown efficacy in melanoma and other malignancies including lung cancer from their immunomodulatory effects. Upon blocking the PD-1 receptor with a checkpoint inhibitor, the negative regulation of the immune system is prevented and subsequently T-cell responses increase. 4 Thus, it follows that such immune activation that targets tumor cells may more broadly activate inflammatory and autoimmune responses including LPP.
A retrospective analysis by Sanlorenzo et al 5 found that patients who had cutaneous adverse events in the setting of pembrolizumab had significantly longer progression-free survival. It remains unclear if lichenoid reactions specifically are associated with positive prognostic outcome, thus these merit further study.
